Review




Structured Review

ViGeneron GmbH aav2.nn
Aav2.Nn, supplied by ViGeneron GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aav2.nn/product/ViGeneron GmbH
Average 90 stars, based on 1 article reviews
aav2.nn - by Bioz Stars, 2026-05
90/100 stars

Images



Similar Products

90
ViGeneron GmbH aav2.nn
Aav2.Nn, supplied by ViGeneron GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aav2.nn/product/ViGeneron GmbH
Average 90 stars, based on 1 article reviews
aav2.nn - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
AAVnerGene Inc aav2.nn-efs-dcasmini-sgpde6b
( A ) Schematic of <t>AAV2.NN</t> backbone and AAV2.NN vectors used for intravitreal injection. ( B ) Bright-field and SLO image of mouse retina showing transduction and spread of vectors 3 weeks after AAV2.NN-CAG-GFP injection. ( C ) Representative retinal cross-sections immunolabeled for GFP after AAV2.NN-CAG-GFP injection for 4 weeks. ( D and E ) WB (D) and IF (E) showing expression of dCasMINI 1 month after intravitreal injection of EFS-dCasMINI into Pde6a nmf363 mice. (D) Representative immunoblots of total lysates and retina cross-sections probed with the antibody against HA. (E) Representative retinal cross sections of 8-week-old mice from each group immunolabeled for HA. ( F ) Quantitative PCR analysis of Pde6b ( N = 4) mRNA levels in sham retina and dCasMINI-treated retina. ( G ) Representative immunoblots of total sham retina and dCasMINI-treated retina lysates and detected with anti-Pde6b antibody. Data are means ± SEM. *** P < 0.001.
Aav2.Nn Efs Dcasmini Sgpde6b, supplied by AAVnerGene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aav2.nn-efs-dcasmini-sgpde6b/product/AAVnerGene Inc
Average 90 stars, based on 1 article reviews
aav2.nn-efs-dcasmini-sgpde6b - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
AAVnerGene Inc serotype aav2.nn
( A ) Schematic of <t>AAV2.NN</t> backbone and AAV2.NN vectors used for intravitreal injection. ( B ) Bright-field and SLO image of mouse retina showing transduction and spread of vectors 3 weeks after AAV2.NN-CAG-GFP injection. ( C ) Representative retinal cross-sections immunolabeled for GFP after AAV2.NN-CAG-GFP injection for 4 weeks. ( D and E ) WB (D) and IF (E) showing expression of dCasMINI 1 month after intravitreal injection of EFS-dCasMINI into Pde6a nmf363 mice. (D) Representative immunoblots of total lysates and retina cross-sections probed with the antibody against HA. (E) Representative retinal cross sections of 8-week-old mice from each group immunolabeled for HA. ( F ) Quantitative PCR analysis of Pde6b ( N = 4) mRNA levels in sham retina and dCasMINI-treated retina. ( G ) Representative immunoblots of total sham retina and dCasMINI-treated retina lysates and detected with anti-Pde6b antibody. Data are means ± SEM. *** P < 0.001.
Serotype Aav2.Nn, supplied by AAVnerGene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/serotype aav2.nn/product/AAVnerGene Inc
Average 90 stars, based on 1 article reviews
serotype aav2.nn - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
AAVnerGene Inc aav2.nn-egfp
( A ) Schematic of <t>AAV2.NN</t> backbone and AAV2.NN vectors used for intravitreal injection. ( B ) Bright-field and SLO image of mouse retina showing transduction and spread of vectors 3 weeks after AAV2.NN-CAG-GFP injection. ( C ) Representative retinal cross-sections immunolabeled for GFP after AAV2.NN-CAG-GFP injection for 4 weeks. ( D and E ) WB (D) and IF (E) showing expression of dCasMINI 1 month after intravitreal injection of EFS-dCasMINI into Pde6a nmf363 mice. (D) Representative immunoblots of total lysates and retina cross-sections probed with the antibody against HA. (E) Representative retinal cross sections of 8-week-old mice from each group immunolabeled for HA. ( F ) Quantitative PCR analysis of Pde6b ( N = 4) mRNA levels in sham retina and dCasMINI-treated retina. ( G ) Representative immunoblots of total sham retina and dCasMINI-treated retina lysates and detected with anti-Pde6b antibody. Data are means ± SEM. *** P < 0.001.
Aav2.Nn Egfp, supplied by AAVnerGene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aav2.nn-egfp/product/AAVnerGene Inc
Average 90 stars, based on 1 article reviews
aav2.nn-egfp - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
AAVnerGene Inc aav2.nn- egfp
( A ) Schematic of <t>AAV2.NN</t> backbone and AAV2.NN vectors used for intravitreal injection. ( B ) Bright-field and SLO image of mouse retina showing transduction and spread of vectors 3 weeks after AAV2.NN-CAG-GFP injection. ( C ) Representative retinal cross-sections immunolabeled for GFP after AAV2.NN-CAG-GFP injection for 4 weeks. ( D and E ) WB (D) and IF (E) showing expression of dCasMINI 1 month after intravitreal injection of EFS-dCasMINI into Pde6a nmf363 mice. (D) Representative immunoblots of total lysates and retina cross-sections probed with the antibody against HA. (E) Representative retinal cross sections of 8-week-old mice from each group immunolabeled for HA. ( F ) Quantitative PCR analysis of Pde6b ( N = 4) mRNA levels in sham retina and dCasMINI-treated retina. ( G ) Representative immunoblots of total sham retina and dCasMINI-treated retina lysates and detected with anti-Pde6b antibody. Data are means ± SEM. *** P < 0.001.
Aav2.Nn Egfp, supplied by AAVnerGene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aav2.nn- egfp/product/AAVnerGene Inc
Average 90 stars, based on 1 article reviews
aav2.nn- egfp - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
AAVnerGene Inc aav2.nn- efs- dcasmini- sgpde6b
( A ) Schematic of <t>AAV2.NN</t> backbone and AAV2.NN vectors used for intravitreal injection. ( B ) Bright-field and SLO image of mouse retina showing transduction and spread of vectors 3 weeks after AAV2.NN-CAG-GFP injection. ( C ) Representative retinal cross-sections immunolabeled for GFP after AAV2.NN-CAG-GFP injection for 4 weeks. ( D and E ) WB (D) and IF (E) showing expression of dCasMINI 1 month after intravitreal injection of EFS-dCasMINI into Pde6a nmf363 mice. (D) Representative immunoblots of total lysates and retina cross-sections probed with the antibody against HA. (E) Representative retinal cross sections of 8-week-old mice from each group immunolabeled for HA. ( F ) Quantitative PCR analysis of Pde6b ( N = 4) mRNA levels in sham retina and dCasMINI-treated retina. ( G ) Representative immunoblots of total sham retina and dCasMINI-treated retina lysates and detected with anti-Pde6b antibody. Data are means ± SEM. *** P < 0.001.
Aav2.Nn Efs Dcasmini Sgpde6b, supplied by AAVnerGene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aav2.nn- efs- dcasmini- sgpde6b/product/AAVnerGene Inc
Average 90 stars, based on 1 article reviews
aav2.nn- efs- dcasmini- sgpde6b - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
ViGeneron GmbH cnga1 vg901/aav2.nn-cnga1
( A ) Schematic of <t>AAV2.NN</t> backbone and AAV2.NN vectors used for intravitreal injection. ( B ) Bright-field and SLO image of mouse retina showing transduction and spread of vectors 3 weeks after AAV2.NN-CAG-GFP injection. ( C ) Representative retinal cross-sections immunolabeled for GFP after AAV2.NN-CAG-GFP injection for 4 weeks. ( D and E ) WB (D) and IF (E) showing expression of dCasMINI 1 month after intravitreal injection of EFS-dCasMINI into Pde6a nmf363 mice. (D) Representative immunoblots of total lysates and retina cross-sections probed with the antibody against HA. (E) Representative retinal cross sections of 8-week-old mice from each group immunolabeled for HA. ( F ) Quantitative PCR analysis of Pde6b ( N = 4) mRNA levels in sham retina and dCasMINI-treated retina. ( G ) Representative immunoblots of total sham retina and dCasMINI-treated retina lysates and detected with anti-Pde6b antibody. Data are means ± SEM. *** P < 0.001.
Cnga1 Vg901/Aav2.Nn Cnga1, supplied by ViGeneron GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cnga1 vg901/aav2.nn-cnga1/product/ViGeneron GmbH
Average 90 stars, based on 1 article reviews
cnga1 vg901/aav2.nn-cnga1 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
ViGeneron GmbH aav2.nn-cnga1 vg-901
( A ) Schematic of <t>AAV2.NN</t> backbone and AAV2.NN vectors used for intravitreal injection. ( B ) Bright-field and SLO image of mouse retina showing transduction and spread of vectors 3 weeks after AAV2.NN-CAG-GFP injection. ( C ) Representative retinal cross-sections immunolabeled for GFP after AAV2.NN-CAG-GFP injection for 4 weeks. ( D and E ) WB (D) and IF (E) showing expression of dCasMINI 1 month after intravitreal injection of EFS-dCasMINI into Pde6a nmf363 mice. (D) Representative immunoblots of total lysates and retina cross-sections probed with the antibody against HA. (E) Representative retinal cross sections of 8-week-old mice from each group immunolabeled for HA. ( F ) Quantitative PCR analysis of Pde6b ( N = 4) mRNA levels in sham retina and dCasMINI-treated retina. ( G ) Representative immunoblots of total sham retina and dCasMINI-treated retina lysates and detected with anti-Pde6b antibody. Data are means ± SEM. *** P < 0.001.
Aav2.Nn Cnga1 Vg 901, supplied by ViGeneron GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aav2.nn-cnga1 vg-901/product/ViGeneron GmbH
Average 90 stars, based on 1 article reviews
aav2.nn-cnga1 vg-901 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


( A ) Schematic of AAV2.NN backbone and AAV2.NN vectors used for intravitreal injection. ( B ) Bright-field and SLO image of mouse retina showing transduction and spread of vectors 3 weeks after AAV2.NN-CAG-GFP injection. ( C ) Representative retinal cross-sections immunolabeled for GFP after AAV2.NN-CAG-GFP injection for 4 weeks. ( D and E ) WB (D) and IF (E) showing expression of dCasMINI 1 month after intravitreal injection of EFS-dCasMINI into Pde6a nmf363 mice. (D) Representative immunoblots of total lysates and retina cross-sections probed with the antibody against HA. (E) Representative retinal cross sections of 8-week-old mice from each group immunolabeled for HA. ( F ) Quantitative PCR analysis of Pde6b ( N = 4) mRNA levels in sham retina and dCasMINI-treated retina. ( G ) Representative immunoblots of total sham retina and dCasMINI-treated retina lysates and detected with anti-Pde6b antibody. Data are means ± SEM. *** P < 0.001.

Journal: Science Advances

Article Title: dCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa

doi: 10.1126/sciadv.adn7540

Figure Lengend Snippet: ( A ) Schematic of AAV2.NN backbone and AAV2.NN vectors used for intravitreal injection. ( B ) Bright-field and SLO image of mouse retina showing transduction and spread of vectors 3 weeks after AAV2.NN-CAG-GFP injection. ( C ) Representative retinal cross-sections immunolabeled for GFP after AAV2.NN-CAG-GFP injection for 4 weeks. ( D and E ) WB (D) and IF (E) showing expression of dCasMINI 1 month after intravitreal injection of EFS-dCasMINI into Pde6a nmf363 mice. (D) Representative immunoblots of total lysates and retina cross-sections probed with the antibody against HA. (E) Representative retinal cross sections of 8-week-old mice from each group immunolabeled for HA. ( F ) Quantitative PCR analysis of Pde6b ( N = 4) mRNA levels in sham retina and dCasMINI-treated retina. ( G ) Representative immunoblots of total sham retina and dCasMINI-treated retina lysates and detected with anti-Pde6b antibody. Data are means ± SEM. *** P < 0.001.

Article Snippet: AAV2.NN-EGFP and AAV2.NN-EFS-dCasMINI-sgPDE6B were packaged by AAVnerGene (North Bethesda, MD).

Techniques: Injection, Transduction, Immunolabeling, Expressing, Western Blot, Real-time Polymerase Chain Reaction

( A and B ) Representative OCT images of the sham retina, AAV2.NN-injected retina, and AAV2.NN-dCasMINI–injected retina in Pde6a nmf363 mice. The green circle showed the OCT scan area surrounding the optical nerve head. GCC indicated in the top red line, and ONL indicated in the bottom red line. ( C ) Statistics for ONL thickness. * P < 0.05. ( D ) DAPI staining of a longitudinal cryosection through the mouse retina. Staining of nuclear DNA demonstrates the retinal layers: PC, layer of outer and inner segments of photoreceptor cells. ( E ) Statistics for ONL thickness. ( F ) Representative image of sham and AAV2.NN-dCasMINI–injected retina staining with recoverin and PNA. Data are presented as means ± SEM; *** P < 0.001, two-tailed unpaired t test. OS, outer segment.

Journal: Science Advances

Article Title: dCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa

doi: 10.1126/sciadv.adn7540

Figure Lengend Snippet: ( A and B ) Representative OCT images of the sham retina, AAV2.NN-injected retina, and AAV2.NN-dCasMINI–injected retina in Pde6a nmf363 mice. The green circle showed the OCT scan area surrounding the optical nerve head. GCC indicated in the top red line, and ONL indicated in the bottom red line. ( C ) Statistics for ONL thickness. * P < 0.05. ( D ) DAPI staining of a longitudinal cryosection through the mouse retina. Staining of nuclear DNA demonstrates the retinal layers: PC, layer of outer and inner segments of photoreceptor cells. ( E ) Statistics for ONL thickness. ( F ) Representative image of sham and AAV2.NN-dCasMINI–injected retina staining with recoverin and PNA. Data are presented as means ± SEM; *** P < 0.001, two-tailed unpaired t test. OS, outer segment.

Article Snippet: AAV2.NN-EGFP and AAV2.NN-EFS-dCasMINI-sgPDE6B were packaged by AAVnerGene (North Bethesda, MD).

Techniques: Injection, Staining, Two Tailed Test

( A and B ) Experimental schematic of in vivo plasmid intravitreal injection at P7. ERG was obtained at 4 weeks after injection. (B) Left eye was sham group, and right eye was injected AAV2.NN. ( C ) Representative the scotopic 0.01, 0.1, and1 cd·s·m −2 dim-light rod-specific ERG traces sham eye and AAV2.NN–injected eye in Pde6a nmf363 mouse. ( D ) Quantification of maximum b-wave amplitude for (C). ( E ) Left: Constructs schematic of in vivo AAV-dCasMINI-sgPDE6B injection. Right: Left eye is sham group and right eye injected AAV2.NN-dCasMINI. ( F ) Representative the scotopic 0.01, 0.1, and 1 cd·s·m −2 dim-light rod-specific ERG traces C57BL/6 eye, AAV2.NN-dCasMINI injected eye, and sham eye in Pde6a nmf363 mouse. ( G and H ) Quantification of maximum a-wave amplitude (G) and b-wave amplitude (H) for (F). Data are presented as means ± SEM; ** P < 0.001, two-tailed unpaired t test. WPI, weeks post-immunization.

Journal: Science Advances

Article Title: dCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa

doi: 10.1126/sciadv.adn7540

Figure Lengend Snippet: ( A and B ) Experimental schematic of in vivo plasmid intravitreal injection at P7. ERG was obtained at 4 weeks after injection. (B) Left eye was sham group, and right eye was injected AAV2.NN. ( C ) Representative the scotopic 0.01, 0.1, and1 cd·s·m −2 dim-light rod-specific ERG traces sham eye and AAV2.NN–injected eye in Pde6a nmf363 mouse. ( D ) Quantification of maximum b-wave amplitude for (C). ( E ) Left: Constructs schematic of in vivo AAV-dCasMINI-sgPDE6B injection. Right: Left eye is sham group and right eye injected AAV2.NN-dCasMINI. ( F ) Representative the scotopic 0.01, 0.1, and 1 cd·s·m −2 dim-light rod-specific ERG traces C57BL/6 eye, AAV2.NN-dCasMINI injected eye, and sham eye in Pde6a nmf363 mouse. ( G and H ) Quantification of maximum a-wave amplitude (G) and b-wave amplitude (H) for (F). Data are presented as means ± SEM; ** P < 0.001, two-tailed unpaired t test. WPI, weeks post-immunization.

Article Snippet: AAV2.NN-EGFP and AAV2.NN-EFS-dCasMINI-sgPDE6B were packaged by AAVnerGene (North Bethesda, MD).

Techniques: In Vivo, Plasmid Preparation, Injection, Construct, Two Tailed Test

( A ) Experimental schematic of in vivo plasmid intravitreal injection at P7 and visual behaviors was assessed at 4 weeks after injection. ( B ) Experiment setup for OKR. ( C ) Number of responders and nonresponders is shown on the y axis with respective percentages. Statistical analysis was performed using Fisher’s exact test. * P < 0.05. ( D ) Experiment setup for looming induced escape behaviors. ( E ) Number of responders and nonresponders to looming is shown on the y axis with respective percentages. Statistical analysis was performed using Fisher’s exact test. ( F ) Statistics for response latency of AAV2.NN- ( N = 5) and dCasMINI-treated mice ( N = 11). Data are presented as means + SEM; *** P < 0.001, two-tailed unpaired t test.

Journal: Science Advances

Article Title: dCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa

doi: 10.1126/sciadv.adn7540

Figure Lengend Snippet: ( A ) Experimental schematic of in vivo plasmid intravitreal injection at P7 and visual behaviors was assessed at 4 weeks after injection. ( B ) Experiment setup for OKR. ( C ) Number of responders and nonresponders is shown on the y axis with respective percentages. Statistical analysis was performed using Fisher’s exact test. * P < 0.05. ( D ) Experiment setup for looming induced escape behaviors. ( E ) Number of responders and nonresponders to looming is shown on the y axis with respective percentages. Statistical analysis was performed using Fisher’s exact test. ( F ) Statistics for response latency of AAV2.NN- ( N = 5) and dCasMINI-treated mice ( N = 11). Data are presented as means + SEM; *** P < 0.001, two-tailed unpaired t test.

Article Snippet: AAV2.NN-EGFP and AAV2.NN-EFS-dCasMINI-sgPDE6B were packaged by AAVnerGene (North Bethesda, MD).

Techniques: In Vivo, Plasmid Preparation, Injection, Two Tailed Test

( A ) Schematic of AAV2.NN backbone and AAV2.NN vectors used for intravitreal injection. ( B ) Bright-field and SLO image of mouse retina showing transduction and spread of vectors 3 weeks after AAV2.NN-CAG-GFP injection. ( C ) Representative retinal cross-sections immunolabeled for GFP after AAV2.NN-CAG-GFP injection for 4 weeks. ( D and E ) WB (D) and IF (E) showing expression of dCasMINI 1 month after intravitreal injection of EFS-dCasMINI into Pde6a nmf363 mice. (D) Representative immunoblots of total lysates and retina cross-sections probed with the antibody against HA. (E) Representative retinal cross sections of 8-week-old mice from each group immunolabeled for HA. ( F ) Quantitative PCR analysis of Pde6b ( N = 4) mRNA levels in sham retina and dCasMINI-treated retina. ( G ) Representative immunoblots of total sham retina and dCasMINI-treated retina lysates and detected with anti-Pde6b antibody. Data are means ± SEM. *** P < 0.001.

Journal: Science Advances

Article Title: dCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa

doi: 10.1126/sciadv.adn7540

Figure Lengend Snippet: ( A ) Schematic of AAV2.NN backbone and AAV2.NN vectors used for intravitreal injection. ( B ) Bright-field and SLO image of mouse retina showing transduction and spread of vectors 3 weeks after AAV2.NN-CAG-GFP injection. ( C ) Representative retinal cross-sections immunolabeled for GFP after AAV2.NN-CAG-GFP injection for 4 weeks. ( D and E ) WB (D) and IF (E) showing expression of dCasMINI 1 month after intravitreal injection of EFS-dCasMINI into Pde6a nmf363 mice. (D) Representative immunoblots of total lysates and retina cross-sections probed with the antibody against HA. (E) Representative retinal cross sections of 8-week-old mice from each group immunolabeled for HA. ( F ) Quantitative PCR analysis of Pde6b ( N = 4) mRNA levels in sham retina and dCasMINI-treated retina. ( G ) Representative immunoblots of total sham retina and dCasMINI-treated retina lysates and detected with anti-Pde6b antibody. Data are means ± SEM. *** P < 0.001.

Article Snippet: AAV2.NN-EGFP and AAV2.NN-EFS-dCasMINI-sgPDE6B were packaged by AAVnerGene (North Bethesda, MD).

Techniques: Injection, Transduction, Immunolabeling, Expressing, Western Blot, Real-time Polymerase Chain Reaction

( A and B ) Representative OCT images of the sham retina, AAV2.NN-injected retina, and AAV2.NN-dCasMINI–injected retina in Pde6a nmf363 mice. The green circle showed the OCT scan area surrounding the optical nerve head. GCC indicated in the top red line, and ONL indicated in the bottom red line. ( C ) Statistics for ONL thickness. * P < 0.05. ( D ) DAPI staining of a longitudinal cryosection through the mouse retina. Staining of nuclear DNA demonstrates the retinal layers: PC, layer of outer and inner segments of photoreceptor cells. ( E ) Statistics for ONL thickness. ( F ) Representative image of sham and AAV2.NN-dCasMINI–injected retina staining with recoverin and PNA. Data are presented as means ± SEM; *** P < 0.001, two-tailed unpaired t test. OS, outer segment.

Journal: Science Advances

Article Title: dCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa

doi: 10.1126/sciadv.adn7540

Figure Lengend Snippet: ( A and B ) Representative OCT images of the sham retina, AAV2.NN-injected retina, and AAV2.NN-dCasMINI–injected retina in Pde6a nmf363 mice. The green circle showed the OCT scan area surrounding the optical nerve head. GCC indicated in the top red line, and ONL indicated in the bottom red line. ( C ) Statistics for ONL thickness. * P < 0.05. ( D ) DAPI staining of a longitudinal cryosection through the mouse retina. Staining of nuclear DNA demonstrates the retinal layers: PC, layer of outer and inner segments of photoreceptor cells. ( E ) Statistics for ONL thickness. ( F ) Representative image of sham and AAV2.NN-dCasMINI–injected retina staining with recoverin and PNA. Data are presented as means ± SEM; *** P < 0.001, two-tailed unpaired t test. OS, outer segment.

Article Snippet: AAV2.NN-EGFP and AAV2.NN-EFS-dCasMINI-sgPDE6B were packaged by AAVnerGene (North Bethesda, MD).

Techniques: Injection, Staining, Two Tailed Test

( A and B ) Experimental schematic of in vivo plasmid intravitreal injection at P7. ERG was obtained at 4 weeks after injection. (B) Left eye was sham group, and right eye was injected AAV2.NN. ( C ) Representative the scotopic 0.01, 0.1, and1 cd·s·m −2 dim-light rod-specific ERG traces sham eye and AAV2.NN–injected eye in Pde6a nmf363 mouse. ( D ) Quantification of maximum b-wave amplitude for (C). ( E ) Left: Constructs schematic of in vivo AAV-dCasMINI-sgPDE6B injection. Right: Left eye is sham group and right eye injected AAV2.NN-dCasMINI. ( F ) Representative the scotopic 0.01, 0.1, and 1 cd·s·m −2 dim-light rod-specific ERG traces C57BL/6 eye, AAV2.NN-dCasMINI injected eye, and sham eye in Pde6a nmf363 mouse. ( G and H ) Quantification of maximum a-wave amplitude (G) and b-wave amplitude (H) for (F). Data are presented as means ± SEM; ** P < 0.001, two-tailed unpaired t test. WPI, weeks post-immunization.

Journal: Science Advances

Article Title: dCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa

doi: 10.1126/sciadv.adn7540

Figure Lengend Snippet: ( A and B ) Experimental schematic of in vivo plasmid intravitreal injection at P7. ERG was obtained at 4 weeks after injection. (B) Left eye was sham group, and right eye was injected AAV2.NN. ( C ) Representative the scotopic 0.01, 0.1, and1 cd·s·m −2 dim-light rod-specific ERG traces sham eye and AAV2.NN–injected eye in Pde6a nmf363 mouse. ( D ) Quantification of maximum b-wave amplitude for (C). ( E ) Left: Constructs schematic of in vivo AAV-dCasMINI-sgPDE6B injection. Right: Left eye is sham group and right eye injected AAV2.NN-dCasMINI. ( F ) Representative the scotopic 0.01, 0.1, and 1 cd·s·m −2 dim-light rod-specific ERG traces C57BL/6 eye, AAV2.NN-dCasMINI injected eye, and sham eye in Pde6a nmf363 mouse. ( G and H ) Quantification of maximum a-wave amplitude (G) and b-wave amplitude (H) for (F). Data are presented as means ± SEM; ** P < 0.001, two-tailed unpaired t test. WPI, weeks post-immunization.

Article Snippet: AAV2.NN-EGFP and AAV2.NN-EFS-dCasMINI-sgPDE6B were packaged by AAVnerGene (North Bethesda, MD).

Techniques: In Vivo, Plasmid Preparation, Injection, Construct, Two Tailed Test

( A ) Experimental schematic of in vivo plasmid intravitreal injection at P7 and visual behaviors was assessed at 4 weeks after injection. ( B ) Experiment setup for OKR. ( C ) Number of responders and nonresponders is shown on the y axis with respective percentages. Statistical analysis was performed using Fisher’s exact test. * P < 0.05. ( D ) Experiment setup for looming induced escape behaviors. ( E ) Number of responders and nonresponders to looming is shown on the y axis with respective percentages. Statistical analysis was performed using Fisher’s exact test. ( F ) Statistics for response latency of AAV2.NN- ( N = 5) and dCasMINI-treated mice ( N = 11). Data are presented as means + SEM; *** P < 0.001, two-tailed unpaired t test.

Journal: Science Advances

Article Title: dCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa

doi: 10.1126/sciadv.adn7540

Figure Lengend Snippet: ( A ) Experimental schematic of in vivo plasmid intravitreal injection at P7 and visual behaviors was assessed at 4 weeks after injection. ( B ) Experiment setup for OKR. ( C ) Number of responders and nonresponders is shown on the y axis with respective percentages. Statistical analysis was performed using Fisher’s exact test. * P < 0.05. ( D ) Experiment setup for looming induced escape behaviors. ( E ) Number of responders and nonresponders to looming is shown on the y axis with respective percentages. Statistical analysis was performed using Fisher’s exact test. ( F ) Statistics for response latency of AAV2.NN- ( N = 5) and dCasMINI-treated mice ( N = 11). Data are presented as means + SEM; *** P < 0.001, two-tailed unpaired t test.

Article Snippet: AAV2.NN-EGFP and AAV2.NN-EFS-dCasMINI-sgPDE6B were packaged by AAVnerGene (North Bethesda, MD).

Techniques: In Vivo, Plasmid Preparation, Injection, Two Tailed Test